دورية أكاديمية
Targeting oncogenic ALK: a promising strategy for cancer treatment.
| العنوان: | Targeting oncogenic ALK: a promising strategy for cancer treatment. |
|---|---|
| المؤلفون: | Grande E; Gastrointestinal and Early Drug Development Unit, Servicio de Oncología Médica, Hospital Ramón y Cajal, Carretera de Colmenar Viejo Km. 9.100, 28034, Madrid, Spain. egrande@oncologiahrc.com, Bolós MV, Arriola E |
| المصدر: | Molecular cancer therapeutics [Mol Cancer Ther] 2011 Apr; Vol. 10 (4), pp. 569-79. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research, Inc., c2001- |
| مواضيع طبية MeSH: | Antineoplastic Agents/*therapeutic use , Enzyme Inhibitors/*therapeutic use , Neoplasms/*drug therapy , Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors, Anaplastic Lymphoma Kinase ; Gene Amplification ; Humans ; Mutation ; Neoplasms/enzymology ; Neoplasms/genetics ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/genetics ; Protein-Tyrosine Kinases/metabolism ; Pyrimidines/therapeutic use ; Receptor Protein-Tyrosine Kinases/genetics ; Receptor Protein-Tyrosine Kinases/metabolism |
| مستخلص: | Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematologic tumors. Novel drugs targeting this tyrosine kinase receptor are under development, and early clinical trials are showing promising activity in non-small cell lung cancer patients with ALK+ tumors. Here, we review the structure and function of the ALK receptor, the mechanisms associated with its deregulation in cancer, methods for ALK detection in tumor samples, its potential as a new marker for candidate patient selection for tailored therapy, and novel drugs under development that target ALK. |
| التعليقات: | Erratum in: Mol Cancer Ther. 2011 Aug;10(8):1529. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (EML4-ALK fusion protein, human) 0 (Enzyme Inhibitors) 0 (NVP-TAE684) 0 (Oncogene Proteins, Fusion) 0 (Pyrimidines) EC 2.7.1.- (p80(NPM-ALK) protein) EC 2.7.10.1 (ALK protein, human) EC 2.7.10.1 (Anaplastic Lymphoma Kinase) EC 2.7.10.1 (Protein-Tyrosine Kinases) EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) |
| تواريخ الأحداث: | Date Created: 20110409 Date Completed: 20110801 Latest Revision: 20220321 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1158/1535-7163.MCT-10-0615 |
| PMID: | 21474455 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1538-8514 |
|---|---|
| DOI: | 10.1158/1535-7163.MCT-10-0615 |